Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16973305 | 0.90 | KMT2A (0.36) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL20788688 | 0.88 | OXTR (0.37) | — | |
| SCHEMBL16973433 | 0.82 | KMT2A (0.40) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL20788679 | 0.82 | KMT2A (0.35) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL16973435 | 0.80 | KMT2A (0.38) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL16973453 | 0.80 | KMT2A (0.41) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL20210961 | 0.79 | OXTR (0.31) | — | |
| SCHEMBL29284677 | 0.79 | KMT2A (0.37) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL30842988 | 0.78 | KMT2A (0.35) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL15474207 | 0.78 | OXTR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077809-A1 | Spirocyclic Derivatives | BASF SE (DE) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077809-A1 | Spirocyclic Derivatives | KEAP1, SAV1, HSP90AA1 | KMT2A 4242/4885MEN1 3596/4885NPC1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.